BNGO Aug 2023 2.000 put
| Previous Close | 1.2500 |
| Open | 1.2500 |
| Bid | 1.1500 |
| Ask | 1.4500 |
| Strike | 2.00 |
| Expire Date | 2023-08-18 |
| Day's Range | 1.2500 - 1.2500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 74 |
- Thomson Reuters StreetEvents
Q1 2023 Bionano Genomics Inc Earnings Call
Q1 2023 Bionano Genomics Inc Earnings Call
Motley FoolBionano Genomics (BNGO) Q1 2023 Earnings Call Transcript
After market close today, Bionano issued a press release announcing its financial results for the first quarter of 2023. Such forward-looking statements are based upon current expectations, and there can be no assurances that the results contemplated in these statements will be realized.
ZacksBionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates
Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -33.33% and 1.72%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireBionano Reports First Quarter 2023 Results and Highlights Recent Business Progress
Q1 2023 revenue was $7.4 million, which represents a 30% increase over Q1 2022Installed base of 259 Saphyr® systems totaled as of Q1 2023, which represents a 47% increase over Q1 2022Sold 5,226 nanochannel array flowcells in Q1 2023, which represents a 62% increase over the number of flowcells sold in Q1 2022Conference call today, May 9, 2023 at 4:30 PM ET SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ende
Motley FoolBetter Gene Sequencing Stock: Illumina vs. Bionano Genomics
Illumina (NASDAQ: ILMN) and Bionano Genomics (NASDAQ: BNGO) might both make gene sequencing devices, but as investments the two couldn't be more different. Whereas Bionano is a new entrant to the market and still has a lot to prove to its investors as well as the scientific community, Illumina is the top dog that's fighting to maintain its position. Bulls argue that Illumina is the better gene sequencing stock because in some sequencing markets, it's basically the only option in town, particularly in the all-important market for next generation sequencers (NGS).
Simply Wall St.Positive Sentiment Still Eludes Bionano Genomics, Inc. (NASDAQ:BNGO) Following 37% Share Price Slump
Unfortunately for some shareholders, the Bionano Genomics, Inc. ( NASDAQ:BNGO ) share price has dived 37% in the last...
GlobeNewswireBionano to Report First Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 9, 2023
SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, May 9, 2023, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2023 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Tuesday, May 9th, 2023Time:4:30 p.m. ETLive call:Toll-Free: (800) 715-9871Conference ID: 4068548Webcast:https://edge.media-server.com/mmc/p/tw7qar43 Participant
- GlobeNewswire
Bionano Announces the Publication of Stockholder Letter Regarding Support for Proxy Proposal
SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced that on May 1, 2023, it published an open letter to stockholders in support of its proposals at its upcoming annual meeting of stockholders, a copy of which is included at the end of this press release. Details of the Annual Meeting of Stockholders The annual meeting of stockholders will be held virtually, via live webcast at www.virtualshareholdermeeting.com/BNGO2023, on June 14, 2023, at 10:00 a.m. Pacif
- GlobeNewswire
Bionano Announces Three Publications Demonstrating OGM’s Utility for Hematological Malignancy Research
Three peer-reviewed publications collectively illustrate the building support in Europe for optical genome mapping (OGM) as a powerful alternative to traditional methods of cytogenetic analysis for hematological malignanciesTaken together, the publications, a review paper and two independent studies, illustrate that OGM is not only comparable to traditional methods of cytogenetic analysis for hematological malignancies but is potentially more sensitive in the detection of relevant aberrations SA
Motley FoolWhy Shares of Bionano Genomics Are Up Monday
Shares of life sciences company Bionano Genomics (NASDAQ: BNGO) were up nearly 14% late Monday afternoon after the genomic testing equipment maker announced preliminary first-quarter numbers. The company, which manufactures the Saphyr optical genome mapping system, said it has 259 of its systems installed, an increase of 47% over the same period last year. The point of the Saphyr is it helps laboratories more efficiently find aberrations in genes that could cause medical disorders.
- GlobeNewswire
UPDATE - Bionano Announces Preliminary Q1 2023 Results and Business Updates
Preliminary Q1 total revenue expected to be between $7.3 and $7.5 million, which would represent an estimated increase of 28% to 32% over Q1 2022Installed base of Saphyr® systems reached 259 as of March 31, 2023, which represents growth of the installed base by 19 systems in the quarter and an increase of 47% over the installed base of 176 Saphyr® systems as of March 31, 2022Preliminary number of nanochannel array flowcells sold in the quarter expected to be 5,226, which would represent an incre
- GlobeNewswire
Bionano Announces Preliminary Q1 2023 Results and Business Updates
Preliminary Q1 total revenue expected to be between $7.3 and $7.5 million, which would represent an estimated increase of 28% to 32% over Q1 2022Installed base of Saphyr® systems reached 259 as of March 31, 2023, which represents growth of the installed base by 19 systems in the quarter and an increase of 47% over the installed base of 176 Saphyr® systems as of March 31, 2022Preliminary number of nanochannel array flowcells sold in the quarter expected to be 5,226, which would represent an incre
- Simply Wall St.
Bionano Genomics (NASDAQ:BNGO) shareholders are still up 117% over 3 years despite pulling back 31% in the past week
Some Bionano Genomics, Inc. ( NASDAQ:BNGO ) shareholders are probably rather concerned to see the share price fall 59...
- GlobeNewswire
Bionano Announces Presentation of OGM Utility Across Cancer Genomics Research Applications at the American Association for Cancer Research (AACR) Annual Meeting
A sponsored session will feature Dr. Ben Finlay from Sanford Burnham Prebys Institute, Dr. Marc Henri Stern from Institut Curie and Dr. Rashmi Kanagal-Shamanna from MD Anderson Cancer Center presenting on the utility of optical genome mapping (OGM) across cancer therapy research and development applicationsFive scientific posters will illustrate the application of OGM in cancer research areas including hematological malignancies, homologous recombination deficiency (HRD), and cell manufacturing
Motley Fool3 Supercharged Growth Stocks With 662% to 741% Upside, According to Wall Street
These fast-paced stocks are on the cutting edge of innovation, and select Wall Street analysts and pundits expect them to skyrocket.
- GlobeNewswire
Bionano Announces Publication that Demonstrates OGM’s Utility for Resolving Complex Genetic Variation in Inherited Retinal Disease
SAN DIEGO, April 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study from researchers at Radboud University Medical Center showing the use of optical genome mapping (OGM) to identify gene disruptive structural variants (SVs) that might contribute to inherited retinal diseases (IRDs). OGM detected a large inversion (173 megabases) impacting the USH2A gene that was initially ignored as a false positive in short-read next-generation sequenci
- GlobeNewswire
Bionano Announces First Study Using OGM to Discover Structural Variants with Potential Relevance to Genetic Diagnosis of MRKH Syndrome, a Syndrome Impacting Reproductive System Development in 1 in 4,500 Females
Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome is among several forms of Müllerian agenesis, a disorder impacting 1 in 4,500 females which is indicated by the absence or underdevelopment of the female reproductive systemResearchers in the study hypothesized that a genome-wide structural variant (SV) analysis would result in the identification of rare SVs relevant to MRKH’s genetic etiology, which might lead to better understanding of the syndrome and ultimately inform potential therapies and tre
Motley FoolBuy This Magnificent Growth Stock Before It's Too Late
Bionano Genomics (NASDAQ: BNGO) appears to be in just that place -- at the start of its growth journey -- and it could be a great way to give your portfolio some additional upside potential. Bionano's claim to fame is its laboratory analyzer device for optical genome mapping, which it calls the Saphyr.
GlobeNewswireBionano Laboratories Expands its Clinical Testing Menu with Launch of OGM-Based Laboratory Developed Tests (LDTs) for Prenatal and Postnatal Analysis
SAN DIEGO, March 15, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the expansion of its clinical testing menu with the launch of two new laboratory developed tests (LDTs) based on optical genome mapping (OGM), OGM-DxTM Postnatal Whole Genome SV and OGM-DxTM Prenatal Whole Genome SV. These LDTs offer a genome-wide assessment of structural variants (SVs) and provide comprehensive testing for most common and rare chromosomal abnormalities. OGM-DxTM Postnatal Whole Genome SV tests pe
- GlobeNewswire
Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) Annual Meeting Featuring OGM Utility Across a Broad Range of Research Applications
Bionano CEO and president Dr. Erik Holmlin will participate with Dr. Bruce Korf, president of the ACMG Foundation, in the foundation’s educational and clinical laboratory genetics and genomics (LGG) awards ceremony by presenting the fellowship awards sponsored by BionanoA scientific session on innovations in genomics will include Dr. Ravindra Kolhe from Augusta University delivering a presentation on the use of optical genome mapping (OGM) for the detection of structural variants (SVs) in consti
- Thomson Reuters StreetEvents
Q4 2022 Bionano Genomics Inc Earnings Call
Q4 2022 Bionano Genomics Inc Earnings Call
- Motley Fool
Bionano Genomics (BNGO) Q4 2022 Earnings Call Transcript
Image source: The Motley Fool. Bionano Genomics (NASDAQ: BNGO)Q4 2022 Earnings CallMar 09, 2023, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day and welcome to the Bionano fourth-quarter and full-year 2022 earnings conference call.
ZacksBionano Genomics, Inc. (BNGO) Reports Q4 Loss, Misses Revenue Estimates
Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -44.44% and 0.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Bionano Genomics Reports Fourth Quarter and Full-Year 2022 Results and Provides Revenue Outlook for 2023
Q4 revenue was $8.2 million, which represents a 30% increase over Q4 20212022 revenue was $27.8 million, which represents a 55% increase over year end 2021Reached installed base of 240 Saphyr® systems as of YE 2022, which represents a 46% increase over YE 2021Conference call today, March 9th, 2023 at 4:30 PM ET SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2022 and reven
Motley FoolIs Bionano Genomics Stock a Buy Now?
In that vein, Bionano Genomics (NASDAQ: BNGO) might be a stock you should consider now. The biggest reason to invest in Bionano Genomics today is that it's bringing in revenue like crazy, and its growth story is just getting started. The company develops and sells a piece of highly specialized genomic mapping hardware dubbed the Saphyr that biomedical researchers use to investigate chromosomal abnormalities called structural variations.
